Tapan Maniar

Tapan Maniar has a comprehensive and diverse work experience in the biopharmaceutical industry. Tapan is currently serving as the Chief Medical Officer at AvenCell, where they are responsible for developing CAR-T therapies and managing a clinical team. Prior to this, they held the position of Senior Vice President of Clinical Development at Dragonfly Therapeutics, Inc. In this role, they led the clinical development of immuno-oncology programs and played a crucial role in the phase 1-2 trial of DF-6002. Before joining Dragonfly Therapeutics, Inc., Tapan Maniar was the Vice President of Clinical Development at Repertoire Immune Medicines, where they focused on developing T-cells loaded with deep primed cytokines. Tapan also worked as a Senior Medical Director at Atara Biotherapeutics, Inc., where they helped lead the development of innovative T-cell therapeutic platforms. Earlier in their career, they held various roles at Amgen Inc., including Global Development Lead and US Medical Affairs Lead. Tapan Maniar began their career in the medical field, completing their Hematology-Oncology Fellowship and Internal Medicine Residency at the Hospital of the University of Pennsylvania. Overall, Tapan Maniar's work experience showcases their expertise in clinical development, regulatory affairs, and medical affairs in the biopharmaceutical industry.

Tapan Maniar attended the University of Pennsylvania School of Medicine from 1999 to 2004, where they obtained a Doctor of Medicine (M.D.) degree.